BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Augment Injectable Bone Graft: Phase III ongoing

In its 3Q11 earnings, BioMimetic said it proposed to expand enrollment to 300 patients in a North American Phase III trial evaluating its Augment Injectable Bone Graft to treat hindfoot fusions. The trial had been designed to enroll 201 patients. The...

Read the full 181 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >